^
    6d
    A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Blincyto (blinatumomab) • Beqalzi (sonrotoclax)
    13d
    BGB-11417-2001-IIT: Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • Beqalzi (sonrotoclax)
    14d
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Recruiting, BeOne Medicines | N=186 --> 500
    Enrollment change • Trial initiation date
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Beqalzi (sonrotoclax)
    17d
    CaDAnCe-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeOne Medicines
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    17d
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia (2025-524366-21-00)
    P2/3, N=161, Not yet recruiting, BeOne Medicines I GmbH
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Beqalzi (sonrotoclax)
    19d
    FLOURISH: Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    20d
    The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Ruijin Hospital
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    20d
    Study of SA+X in the Treatment of Newly Diagnosed AML (clinicaltrials.gov)
    P2, N=205, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Xospata (gilteritinib) • azacitidine • Tibsovo (ivosidenib) • Beqalzi (sonrotoclax)
    21d
    SONIC: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 30
    Enrollment change
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs) • Beqalzi (sonrotoclax) • Mabtas (rituximab biosimilar)
    28d
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Beqalzi (sonrotoclax)
    1m
    BGB-11417-105: A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=246, Recruiting, BeOne Medicines | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide • Beqalzi (sonrotoclax)
    1m
    A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Beqalzi (sonrotoclax) • catadegbrutinib (BGB-16673)